Neyran Kertmen

Sie schloss 2004 die Medizinische Fakultät der Universität Gazi ab. Ihre Facharztausbildung in Innerer Medizin beendete sie 2009 am Lehr- und Forschungskrankenhaus S.B. Dışkapı Yıldırım Beyazıt. Die Zusatzfacharztausbildung in der Einheit für Medizinische Onkologie der Abteilung für Innere Medizin der Medizinischen Fakultät der Universität Hacettepe schloss sie 2013 ab und wurde Fachärztin für Medizinische Onkologie. 2017 wurde sie Assoz. Professorin.

2015 erhielt sie den Prof.-Dr.-Ali-Haydar-Taşpınar-Preis der Türkischen Stiftung zur Krebsbekämpfung.

Prof. Dr. Neyran Kertmen ist derzeit in der Abteilung für Medizinische Onkologie der Universität Hacettepe tätig.

1. Digital multiplex ligation-dependent probe amplification identifies exon-level copy number variants in patients with suspected hereditary cancer and negative next-generation sequencing resultsDURMAZ ÖZDİNÇ C. D., Bulut N. S., ERKAN KOLAÇ D. D., KERTMEN N., AKÇİN Ö. Ç., DİZDAR Ö., et al.Molecular Biology Reports, cilt.53, sa.1, 2026 (SCI-Expanded, Scopus)
2. Serum Vitamin D Levels as a Prognostic Biomarker in Patients Receiving Immune Checkpoint InhibitorsŞahi̇n T. K., BAŞ O., KAVGACI G., Güdük N., ŞİRVAN F., AKIN S., et al.Journal of Oncological Science, cilt.12, sa.1, ss.1-8, 2026 (Scopus, TRDizin)
3. Prognostic significance of ductal carcinoma in situ coexisting with invasive ductal carcinoma: Biological behavior, immune response and survival outcomesFedai N. K., Koc I., KAVGACI G., ÜNER M., ÜNER A., AKSOY S., et al.Molecular and Clinical Oncology, cilt.24, sa.1, 2026 (ESCI, Scopus)
4. Advancing Intracranial Tumor Treatment Through Gyroscopic Radiosurgery-Based Lattice Therapy: Evidence From a Case Series Study.Yilmaz M. T., Yedekci F. Y., Mohammadipour S., Kivanc H., Cengiz M., Cifci G., et al.Cureus, cilt.17, sa.6, 2025 (ESCI)
5. Sequential immunotherapy and bevacizumab treatments in glioblastoma multiforme: A case series and review of the literatureKERTMEN N., KAVGACI G., Koc I., PARLAK SAĞOL Ş., IŞIKAY A. İ., YAZICI G.ONCOLOGY LETTERS, cilt.29, sa.3, 2025 (SCI-Expanded, Scopus)
6. Evaluating Immunotherapy Responses in Neuro-Oncology for Glioblastoma and Brain Metastases: A Brief Review Featuring Three CasesKERTMEN N., KAVGACI G., AKIN S., ÇOBAN ÇİFÇİ G., IŞIKAY A. İ., YAZICI G.CANCER CONTROL, cilt.32, 2025 (SCI-Expanded, Scopus)
7. Hypo-fractionated Stereotactic Re-Irradiation Outcomes For Recurrent GlioblastomaYilmaz M. T., KAHVECİOĞLU A., Mohammadipur S., Zorlu F., Oge K., KERTMEN N., et al.RADIOTHERAPY AND ONCOLOGY, 2024 (SCI-Expanded, Scopus)
8. Hypofractionated stereotactic re-irradiation for progressive glioblastoma: twelve years’ experience of a single centerYilmaz M. T., KAHVECİOĞLU A., YAZICI G., Mohammadipour S., KERTMEN N., Cifci G. C., et al.Journal of Neuro-Oncology, cilt.167, sa.2, ss.295-303, 2024 (SCI-Expanded, Scopus)
9. Acute heart failure following pazopanib treatment: a literature review featuring two case reportsKERTMEN N., KAVGACI G., YILDIRIM H. Ç., DİZDAR Ö.Anti-Cancer Drugs, cilt.35, sa.3, ss.302-304, 2024 (SCI-Expanded, Scopus)
10. Comparison of different target volume delineation strategies based on recurrence patterns in adjuvant radiotherapy for glioblastoma.Yilmaz M. T., Kahvecioglu A., Yedekci F. Y., Yigit E., Ciftci G. C., Kertmen N., et al.Neuro-oncology practice, cilt.11, sa.3, ss.275-283, 2024 (ESCI, Scopus)
11. Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency AnemiaAKTAŞ B. Y., ATA E. B., ÇEŞMECİ E., ÇAKIR İ. Y., Coşkunpınar M., TAHILLIOĞLU Y., et al.Current Oncology, cilt.30, sa.11, ss.9689-9700, 2023 (SCI-Expanded, Scopus)
12. Low-grade glial tumors: The experience of an oncology hospital in TürkiyeCEYLAN S., KERTMEN N., YAZICI G., KARS A.Acta Medica, cilt.54, sa.2, ss.151-156, 2023 (TRDizin)
13. SMART syndrome: a case reportBozkurt S., Toprak B., YILDIRIM H. Ç., PARLAK SAĞOL Ş., GÜVEN D. C., KERTMEN N., et al.ACTA NEUROLOGICA BELGICA, cilt.123, sa.3, ss.1137-1140, 2023 (SCI-Expanded, Scopus)
14. KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancerKUŞ F., Guven D. C., YILDIRIM H. Ç., Chalabiyev E., AKYILDIZ A., Tatar O. D., et al.Biomarkers in Medicine, cilt.17, sa.7, ss.379-389, 2023 (SCI-Expanded, Scopus)
15. Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatmentGuven D. C., YILDIRIM H. Ç., KUŞ F., Erul E., KERTMEN N., DİZDAR Ö., et al.Expert Review of Anticancer Therapy, cilt.23, sa.10, ss.1049-1059, 2023 (SCI-Expanded, Scopus)
16. Lesson learned from the pandemic: Isolation and hygiene measures for COVID-19 could reduce the nosocomial infection rates in oncology wardsGÜVEN D. C., EROĞLU İ., Ismayilov R., ULUSOYDAN E., AKTEPE O. H., TELLİ DİZMAN G., et al.JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.28, sa.8, ss.1807-1811, 2022 (SCI-Expanded, Scopus)
17. Cerebellar Hypermetabolism: An Alternative Marker for Diagnosis of Paraneoplastic Cerebellar Degeneration.Arslan D., Ardıc F. S., Gultekin-Zaim O. B., Tuncel M., Kertmen N., Gocmen R., et al.Neurologia (Barcelona, Spain), 2022 (Hakemli Dergi)
18. THSD7A expression: a novel immunohistochemical determinant in predicting overall survival of metastatic renal cell carcinoma treated with targeted therapyAktepe O. H., Gundogdu F., Kosemehmetoglu K., Yeter H. H., Aksoy S., Guven D. C., et al.IRISH JOURNAL OF MEDICAL SCIENCE, cilt.191, sa.4, ss.1561-1567, 2022 (SCI-Expanded, Scopus)
19. Comparison of Clinical and Pathological Factors Affecting Early and Late Recurrences in Patients with Operable Breast CancerYEKEDÜZ E., DİZDAR Ö., KERTMEN N., AKSOY S.JOURNAL OF CLINICAL MEDICINE, cilt.11, sa.9, 2022 (SCI-Expanded, Scopus)
20. HER2-low breast cancer could be associated with an increased risk of brain metastasisGÜVEN D. C., KAYA M. B., Fedai B., ÖZDEN M., YILDIRIM H. Ç., KÖSEMEHMETOĞLU K., et al.INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, cilt.27, sa.2, ss.332-339, 2022 (SCI-Expanded, Scopus)
21. Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experienceDiker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., TABAN H., et al.FUTURE ONCOLOGY, cilt.18, ss.323-331, 2022 (SCI-Expanded, Scopus)
22. The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life studyGÜVEN D. C., YILDIRIM H. Ç., ERUL E., ŞAHİN T. K., ÇAKIR İ. Y., AKTEPE O. H., et al.TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.52, sa.5, ss.1551-1558, 2022 (SCI-Expanded, Scopus, TRDizin)
23. The association of BMI and sarcopenia with survival in patients with glioblastoma multiformeGÜVEN D. C., AKSUN M. S., ÇAKIR İ. Y., KILIÇKAP S., KERTMEN N.FUTURE ONCOLOGY, cilt.17, ss.4405-4413, 2021 (SCI-Expanded, Scopus)
24. Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortalityGÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., Incesu F. G. G., TAHILLIOĞLU Y., et al.BMJ SUPPORTIVE & PALLIATIVE CARE, 2021 (SCI-Expanded, Scopus)
25. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapyGÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., et al.SUPPORTIVE CARE IN CANCER, cilt.29, sa.9, ss.5417-5423, 2021 (SCI-Expanded, Scopus)
26. Sarcopenia and anthracycline cardiotoxicity in patients with cancerBAŞ O., ERDEMİR A. G., ONUR M. R., ÖZER N., ŞENER Y. Z., AKSU S., et al.BMJ SUPPORTIVE & PALLIATIVE CARE, 2021 (SCI-Expanded, Scopus)
27. Does Combined Fractionated Stereotactic Radiotherapy and Immunotherapy Change the Outcome of Recurrent High-Grade Gliomas?Sari S. Y., AKTAŞ B. Y., KERTMEN N., ELMALI A., Kilickap S., Oguz K. K., et al.CUREUS, cilt.13, sa.6, 2021 (ESCI)
28. Adjuvant treatment with paclitaxel plus trastuzumab for node negative human epidermal growth factor receptor 2-positive breast cancer: Real life experienceDiker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., Olgun P., et al.CANCER RESEARCH, cilt.81, sa.4, 2021 (SCI-Expanded, Scopus)
29. COVID-19 pandemic: changes in cancer admissions.Guven D. C., Aktas B. Y., Aksun M. S., Ucgul E., Sahin T. K., Yildirim H. C., et al.BMJ supportive & palliative care, 2020 (SCI-Expanded, Scopus)
30. Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinomaBAŞ O., Ozbek A., Guven D., Aktepe O., KILIÇ L., KERTMEN N., et al.JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.26, sa.5, ss.1230-1233, 2020 (SCI-Expanded, Scopus)
31. Depression and anxiety in oncology nurses.Keskin O., Oktay E., Turan M., Kertmen N., Tanriverdi O., Imamoglu G. I., et al.JOURNAL OF CLINICAL ONCOLOGY, cilt.36, sa.15, 2018 (SCI-Expanded, Scopus)
32. Comparison of prognosis and clinical features between synchronous bilateral and unilateral breast cancersKarakas Y., KERTMEN N., LAÇİN Ş., Aslan A., DEMİR M., ATEŞ Ö., et al.JOURNAL OF BUON, cilt.22, sa.3, ss.623-627, 2017 (SCI-Expanded, Scopus)
33. Correlation of educational status and clinicopathological characteristics of breast cancer: a single center experienceSarici F., BABACAN T., Buyukhatipoglu H., Balakan O., SEVER A. R., KERTMEN N., et al.JOURNAL OF BUON, cilt.21, sa.4, ss.826-831, 2016 (SCI-Expanded, Scopus)
34. Assessment of psychosocial factors and distress in women having adjuvant endocrine therapy for breast cancer: the relationship among emotional distress and patient and treatment-related factorsATEŞ Ö., SOYLU C., BABACAN T., Sarici F., KERTMEN N., Allen D., et al.SPRINGERPLUS, cilt.5, 2016 (SCI-Expanded, Scopus)
35. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancerATEŞ Ö., BABACAN T., KERTMEN N., Sarici F., Cenoli A., AKIN S., et al.JOURNAL OF BUON, cilt.21, sa.2, ss.375-381, 2016 (SCI-Expanded, Scopus)
36. Anthracyclin - Based Chemotherapy in Patients with Non-Hodgkin Lymphoma Aged Over 75Sarici F., KERTMEN N., Aslan A. C., Tasdemir V., BABACAN T., KILIÇKAP S., et al.UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.26, sa.2, ss.89-95, 2016 (SCI-Expanded, Scopus, TRDizin)
37. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancerBABACAN T., Efe O., Hasirci A. S., Demirci F., Buyukhatipoglu H., Balakan O., et al.TUMORI J, cilt.101, sa.4, ss.418-423, 2015 (SCI-Expanded, Scopus)
38. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortalitySolak M., Turkoz F. P., Keskin O., AKSOY S., BABACAN T., Sarici F., et al.JOURNAL OF BUON, cilt.20, sa.3, ss.737-745, 2015 (SCI-Expanded, Scopus)
39. Chemotherapy might not be beneficial in lymph node-negative, hormone-positive, and HER2-negative breast cancer patients: a long-term retrospective analysisBABACAN T., Buyukhatipoglu H., Balakan O., KERTMEN N., Suner A., Sarici F., et al.JOURNAL OF BUON, cilt.20, sa.2, ss.479-486, 2015 (SCI-Expanded, Scopus)
40. The effect of renin-angiotensin-system inhibition on survival and recurrence of N3+breast cancer patientsBABACAN T., Balakan O., Kuzan T. Y., Sarici F., Koca E., KERTMEN N., et al.JOURNAL OF BUON, cilt.20, sa.1, ss.50-56, 2015 (SCI-Expanded, Scopus)
41. which sequence best protects the heart against trastuzumab and anthracycline toxicity? An electron microscopy study in ratsKERTMEN N.Hacettepe Journal of Biology and Chemistry, cilt.15, ss.1056-1058, 2015 (Scopus, TRDizin)
42. Comparison of three different induction regimens for nasopharyngeal cancerKERTMEN N., AKSOY S., CENGİZ M., YAZICI G., KESKİN O., Babacan T., et al.Asian Pacific Journal of Cancer Prevention, cilt.16, sa.1, ss.59-63, 2015 (SCI-Expanded, Scopus)
43. Molecular subtypes in patients with inflammatory breast cancer; A single center experienceKERTMEN N., BABACAN T., Keskin O., Solak M., Sarici F., AKIN S., et al.JOURNAL OF BUON, cilt.20, sa.1, ss.35-39, 2015 (SCI-Expanded, Scopus)
44. A systemic late recurrence after the first operation in a patient diagnosed with early-stage breast cancer: the latest recurrence in the literatureKeskin O. D., KERTMEN N., Karakas Y., BABACAN T., ARIK Z., Altundag K., et al.JOURNAL OF BUON, cilt.20, sa.1, ss.348, 2015 (SCI-Expanded, Scopus)
45. A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancerBuyukhatipoglu H., BABACAN T., KERTMEN N., Balakan O., Suner A., ATEŞ Ö., et al.JOURNAL OF BUON, cilt.20, sa.1, ss.22-27, 2015 (SCI-Expanded, Scopus)
46. Acquired C1 esterase inhibitor deficiency in a marginal zone lymphoma patient treated with rituximabATEŞ Ö., Sunar V., BABACAN T., AKIN S., KERTMEN N., Altundag K.JOURNAL OF BUON, cilt.20, sa.1, ss.349, 2015 (SCI-Expanded, Scopus)
47. Which sequence best protects the heart against trastuzumab and anthracycline toxicity An electron microscopy study in ratsKERTMEN N., AKSOY S., ÜNER A., ÖZGÜR Ö., keskin o., babacan t., et al.Anticancer Research, 2015 (SCI-Expanded, Scopus)
48. Association between common risk factors and molecular subtypes in breast cancer patientsTurkoz F. P., Solak M., Petekkaya I., Keskin O., KERTMEN N., Sarici F., et al.BREAST, cilt.22, sa.3, ss.344-350, 2013 (SCI-Expanded, Scopus)

1. Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology HospitalGuven D. C., AKTEPE O. H., Berk Z., Guner G., Taban H., AKTAŞ B. Y., et al.44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, (Özet Bildiri)
2. Onkoloji Hemşirelerinde depresyon ve anksiyeteKESKİN Ö., OKTAY E., TURAN M., KERTMEN N., TANRIVERDİ Ö., İMAMOĞLU G. İ., et al.22.ULUSAL KANSER KONGRESİ, Türkiye, 19 - 23 Nisan 2017, (Özet Bildiri)
3. TRASTUZUMAB KARDİYOTOKSİSİTESİNİ İMMUNGLOBULİN /- STEROİD UYGULAMASI ÖNLEYEBİLİR Mİ?, TAVŞAN MODELİ HAYVAN DENEYİKERTMEN N., AKSOY S., ERMİŞ D. Y., KESKİN Ö., SOLAK M., ARIK Z., et al.22. UKK, Türkiye, 19 - 23 Nisan 2017, (Özet Bildiri)
4. Clinicopathologic characteristics of patients with recurrent or metastatic synovial sarcomaATEŞ Ö., AKSOY S., YETER H. H., Akın S., KERTMEN N., DİZDAR Ö., et al.2016 ASCO Annual Meeting, 29 Mayıs - 03 Haziran 2016, (Tam Metin Bildiri)
5. Kadri Altundag Taner Babacan Orhan Efe Ahmet S Hasırcı Fatih Demirci Hakan Buyukhatıpoglu Ozan Balakan Furkan Saim Sarıcı Neyran Kertmen Ece Esin Serkan Akin Ozturk Ates Sercan Aksoy Ali R SeverALTUNDAĞ M. K., Babacan T., EFE O., HASIRCI A. S., DEMİRCİ F., BUYUKHATİPOGLU H., et al.2015 ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri)
6. Tumor locations significantly affect disease free survival and overall survivalBUYUKHATİPOGLU H., Babacan T., KERTMEN N., Ateş Ö., AKTAŞ G., ŞENDUR M. A. N., et al.2015 ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri)
7. Signet ring cell carcinoma of breast: Single center experience.AKIN S., DIKER O., KERTMEN N., ATEŞ Ö., DİZDAR Ö., YALÇIN Ş., et al.Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)
8. Which sequence prevents the heart from trastuzumab and anthracycline toxicity: Electron microscopy study in ratsAksoy S., Kertmen N., ÜNER A., Sargon M., Ozkayar O., Keskin O., et al.50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri)
9. Clinicopathologic characteristics of pure papillary breast carcinomaTurkoz F. P., Solak M., Keskin O., Arik Z., Arslan C., Kertmen N., et al.49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
10. The impact of adjuvant delayed radiotheraphy (RT) on survival in patients with resected periampullary adenocarcinomas.Yalcin S., Kertmen N., Yuce D., Yildiz F., Hamaloglu E.49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
11. Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe experienceAKSOY S., DEĞİRMENCİLER R. F., AKTAŞ B. Y., Guven D. C., AKTEPE O. H., Guner G., et al.
12. Effectiveness and safety of ferric carboxymaltose to treat iron deficiency anemia in cancer patients.Aktas B. Y., Kayku V. E., Aslan A., Kertmen N., Dizdar Ö., Yalcin S., et al.
13. Depression and anxiety in oncology nurses.KESKİN Ö., OKTAY E., TURAN M., KERTMEN N., TANRIVERDİ Ö., İMAMOĞLU İNANÇ G., et al.
14. Intravenous ferric carboxymaltose treatment in cancer patientsASLAN A., TAŞDEMİR V., KERTMEN N., DİZDAR Ö., AKSOY S.
15. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancerAteş Ö., Babacan T., SARICI F., KERTMEN N., CENOLİ A., Akın S., et al.
16. Neuroendocrine breast cancer A single center experienceTAŞDEMİR V., Kertmen N., CENOLİ A., KESKİN Ö., KARAKAS Y., Diker Ö., et al.
17. Correlation of educational status and clinicopathological characteristics of breast cancer: A single center experience.Diker O., Babacan T., Buyukhatipoglu H., Kertmen N., Balakan O., Sever A. R., et al.
18. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer.Altundag K., Babacan T., Efe O., Hasirci A. S., Demirci F., Buyukhatipoglu H., et al.
19. Comparison of three different induction regimen in nasopharyngeal cancer: CF versus DC versus DCF.Kertmen N., Aksoy S., Cengiz M., Yazici G., Keskin O., Babacan T., et al.
20. Association of the neutrophil to lymphocyte ratio with survival patients with in metastatic breast cancer.Unlu O., Aygun S., Petekkaya H., Gecmez G., Roach E. C., Babacan T., et al.